Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 3/20 | 0.51 |
| ▸ | CES1 | P23141 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530737 | 1.00 | HDAC4 (0.53) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL9298252 | 1.00 | HDAC4 (0.53) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL29531136 | 0.85 | HDAC4 (0.50) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL9298388 | 0.85 | HDAC4 (0.50) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL7463303 | 0.85 | EPHX1 (0.50) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL9298392 | 0.85 | HDAC4 (0.50) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL3711116 | 0.82 | SRC (0.58) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL7680005 | 0.81 | CES2 (0.45) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL75778 | 0.80 | HDAC4 (0.50) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL29449418 | 0.80 | HDAC4 (0.50) | HDAC4HDAC7HDAC5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730918-A | Aporphine derivative, and preparation method and application thereof | 苏州大学 | 2023-09-12 | — | — | CN | disclosed |
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116003434-A | Macrocyclic compound and medical application thereof | 中国药科大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-110325528-B | 2-benzopyrazinyl-N-heteroaryl-2-phenyl-acetamide compounds | 豪夫迈·罗氏有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-115108986-A | Aporphine derivative and preparation method and application thereof | 苏州大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-112920105-B | Phthalimide compound and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2022-03-22 | — | — | CN | disclosed |
| EP-3558967-B1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-03-02 | — | — | EP | disclosed |
| CN-112920105-A | Phthalimide compound and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2021-06-08 | — | — | CN | disclosed |
| CN-112624972-A | Acridone compound and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-04-09 | — | — | CN | disclosed |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| EP-1893575-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H.Lundbeck A/S (DK) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134499-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| CN-1292697-A | Anti-viral compound | LILLY CO ELI (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5374656-A | Nervous system disorders, gastrointestinal disorders | RHONE-POULENC RORER, S.A. (FR) | 1994-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | HDAC4 3052/4885HDAC7 1438/4885HDAC5 882/4885 |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | HDAC4 3052/4885HDAC7 1438/4885HDAC5 882/4885 |
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | CYP11B2, CYP1A2, CYP4B1 | HDAC4 989/4885HDAC7 1554/4885HDAC5 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.